Olson Eric R 4
4 · Syros Pharmaceuticals, Inc. · Filed Feb 17, 2022
Insider Transaction Report
Form 4
Olson Eric R
Chief Scientific Officer
Transactions
- Award
Restricted Stock Units
2022-02-15+200,000→ 200,000 total→ Common Stock (200,000 underlying) - Award
Stock Option (right to buy)
2022-02-15+100,000→ 100,000 totalExercise: $1.59Exp: 2032-02-14→ Common Stock (100,000 underlying) - Award
Restricted Stock Units
2022-02-15+80,000→ 80,000 total→ Common Stock (80,000 underlying)
Footnotes (4)
- [F1]This option becomes exercisable as to one quarter (1/4th) of the shares on February 28, 2023, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter.
- [F2]Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
- [F3]These RSUs will vest in four equal annual installments commencing on March 31, 2023.
- [F4]These RSUs will vest in full on March 31, 2025.